Biocon Ltd
Biocon is engaged in the business of manufacture of biotechnology products and research services.(Source : 202003-01 Annual Report Page No:195)
- Market Cap ₹ 28,844 Cr.
- Current Price ₹ 240
- High / Low ₹ 344 / 192
- Stock P/E 47.0
- Book Value ₹ 149
- Dividend Yield 0.62 %
- ROCE 6.50 %
- ROE 4.66 %
- Face Value ₹ 5.00
Pros
- Company is expected to give good quarter
Cons
- Company has a low return on equity of 7.26% over last 3 years.
- Company might be capitalizing the interest cost
- Debtor days have increased from 95.1 to 117 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2,086 | 2,485 | 2,877 | 3,090 | 3,347 | 3,891 | 4,123 | 5,514 | 6,300 | 7,143 | 8,184 | 11,174 | |
1,569 | 1,942 | 2,190 | 2,394 | 2,957 | 2,912 | 3,294 | 4,121 | 4,725 | 5,562 | 6,418 | 8,830 | |
Operating Profit | 517 | 543 | 687 | 696 | 390 | 980 | 829 | 1,394 | 1,575 | 1,581 | 1,766 | 2,345 |
OPM % | 25% | 22% | 24% | 23% | 12% | 25% | 20% | 25% | 25% | 22% | 22% | 21% |
62 | 255 | 56 | 158 | 639 | 173 | 228 | 340 | 228 | 260 | 99 | 84 | |
Interest | 12 | 8 | 2 | 9 | 29 | 26 | 62 | 71 | 65 | 58 | 68 | 419 |
Depreciation | 174 | 179 | 204 | 221 | 249 | 277 | 385 | 448 | 552 | 715 | 814 | 1,113 |
Profit before tax | 392 | 610 | 538 | 624 | 751 | 850 | 610 | 1,215 | 1,186 | 1,068 | 983 | 897 |
Tax % | 14% | 16% | 20% | 15% | 19% | 19% | 26% | 17% | 27% | 21% | 22% | 28% |
Net Profit | 338 | 513 | 431 | 528 | 609 | 688 | 453 | 1,003 | 871 | 846 | 772 | 643 |
EPS in Rs | 2.82 | 4.24 | 3.45 | 4.14 | 4.59 | 5.10 | 3.10 | 7.54 | 6.24 | 6.17 | 5.40 | 3.85 |
Dividend Payout % | 30% | 29% | 24% | 20% | 18% | 10% | 16% | 7% | 0% | 0% | 9% | 39% |
Compounded Sales Growth | |
---|---|
10 Years: | 16% |
5 Years: | 22% |
3 Years: | 21% |
TTM: | 37% |
Compounded Profit Growth | |
---|---|
10 Years: | 6% |
5 Years: | 13% |
3 Years: | -4% |
TTM: | -14% |
Stock Price CAGR | |
---|---|
10 Years: | 18% |
5 Years: | -5% |
3 Years: | -15% |
1 Year: | -25% |
Return on Equity | |
---|---|
10 Years: | 9% |
5 Years: | 9% |
3 Years: | 7% |
Last Year: | 5% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
100 | 100 | 100 | 100 | 100 | 100 | 300 | 300 | 600 | 600 | 600 | 600 | |
Reserves | 2,172 | 2,595 | 2,927 | 3,171 | 3,934 | 4,738 | 4,881 | 5,798 | 6,106 | 7,027 | 7,832 | 17,267 |
271 | 267 | 864 | 1,117 | 2,478 | 2,302 | 2,264 | 2,422 | 2,715 | 4,481 | 5,147 | 18,019 | |
1,402 | 1,454 | 1,860 | 1,988 | 1,947 | 2,254 | 2,545 | 3,672 | 4,993 | 6,382 | 6,763 | 16,157 | |
Total Liabilities | 3,945 | 4,416 | 5,751 | 6,375 | 8,458 | 9,394 | 9,990 | 12,192 | 14,414 | 18,490 | 20,342 | 52,043 |
1,270 | 1,510 | 1,525 | 1,630 | 1,748 | 3,626 | 3,700 | 4,471 | 5,971 | 6,364 | 6,569 | 34,197 | |
CWIP | 390 | 312 | 1,206 | 1,677 | 2,240 | 839 | 1,303 | 1,899 | 2,196 | 2,800 | 4,110 | 2,588 |
Investments | 556 | 587 | 765 | 230 | 902 | 1,253 | 675 | 1,012 | 966 | 1,952 | 1,588 | 2,069 |
1,729 | 2,007 | 2,255 | 2,839 | 3,569 | 3,676 | 4,312 | 4,811 | 5,281 | 7,374 | 8,074 | 13,189 | |
Total Assets | 3,945 | 4,416 | 5,751 | 6,375 | 8,458 | 9,394 | 9,990 | 12,192 | 14,414 | 18,490 | 20,342 | 52,043 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
594 | 471 | 561 | 211 | 371 | 640 | 662 | 1,155 | 1,283 | 1,160 | 1,177 | 1,852 | |
-398 | -358 | -904 | -491 | -1,138 | -510 | -684 | -703 | -1,505 | -3,651 | -1,662 | -14,282 | |
-186 | -9 | 426 | 186 | 1,068 | -178 | -240 | -242 | 388 | 2,564 | 242 | 13,049 | |
Net Cash Flow | 10 | 105 | 83 | -94 | 300 | -47 | -261 | 210 | 165 | 72 | -243 | 619 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 86 | 75 | 76 | 91 | 78 | 83 | 94 | 86 | 71 | 77 | 92 | 117 |
Inventory Days | 162 | 139 | 116 | 132 | 153 | 160 | 161 | 199 | 263 | 304 | 309 | 423 |
Days Payable | 149 | 121 | 107 | 125 | 172 | 187 | 224 | 231 | 243 | 246 | 216 | 397 |
Cash Conversion Cycle | 99 | 93 | 85 | 98 | 59 | 57 | 31 | 53 | 91 | 134 | 184 | 143 |
Working Capital Days | 27 | 21 | -0 | 12 | 31 | 34 | 18 | 15 | 8 | 80 | 112 | 129 |
ROCE % | 16% | 15% | 16% | 13% | 9% | 13% | 8% | 13% | 13% | 10% | 9% | 6% |
Documents
Announcements
-
Notification To Stock Exchange
1d - The US FDA concluded a surveillance and pre-approval inspection of Biocon Pharma Limited Oral Solid Dosage formulations manufacturing facility at Bengaluru on 2nd June 2023, …
- Intimation Under Regulation 30 (6) Of SEBI LODR (LODR) Regulations, 2015. 2d
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
31 May - Letter dated May 24, 2023 regarding presentation and video recording of Q4 and full year FY23 Earnings Call held on May 24, 2023, please find …
- Intimation Under Regulation 30 (6) Of SEBI LODR (LODR) Regulations, 2015. 31 May
- Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of SEBI (Listing Obligation And Disclosure Requirements) Regulation, 2015 ('SEBI Listing Regulation'). 26 May
Annual reports
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
-
Financial Year 2010
from bse
-
Financial Year 2010
from nse
Concalls
-
May 2023Transcript PPT
-
May 2023TranscriptNotesPPT
-
Feb 2023Transcript PPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022Transcript PPT
-
Nov 2022TranscriptNotesPPT
-
Nov 2022TranscriptNotesPPT
-
Aug 2022Transcript PPT
-
Jul 2022TranscriptNotesPPT
-
May 2022Transcript PPT
-
Apr 2022TranscriptNotesPPT
-
Apr 2022TranscriptNotesPPT
-
Feb 2022Transcript PPT
-
Jan 2022TranscriptNotesPPT
-
Nov 2021Transcript PPT
-
Oct 2021TranscriptPPT
-
Sep 2021Transcript PPT
-
Sep 2021TranscriptPPT
-
Jul 2021TranscriptPPT
-
May 2021Transcript PPT
-
Apr 2021TranscriptNotesPPT
-
Jan 2021TranscriptPPT
-
Oct 2020Transcript PPT
-
Jul 2020Transcript PPT
-
Jun 2020Transcript PPT
-
Feb 2020Transcript PPT
-
Dec 2019TranscriptNotesPPT
-
Dec 2019Transcript PPT
-
Sep 2019TranscriptNotesPPT
-
Sep 2019Transcript PPT
-
Jun 2019TranscriptNotesPPT
-
May 2019Transcript PPT
-
Feb 2019Transcript PPT
-
Nov 2018Transcript PPT
-
Sep 2018TranscriptNotesPPT
-
Jun 2018Transcript PPT
-
Mar 2018TranscriptPPT
-
Feb 2018Transcript PPT
-
Oct 2017Transcript PPT
-
Aug 2017TranscriptPPT
-
Apr 2017Transcript PPT
-
Feb 2017TranscriptPPT
-
Oct 2016TranscriptPPT
-
Jul 2016TranscriptPPT
-
Apr 2016TranscriptPPT
-
Jan 2016TranscriptPPT
-
Oct 2015TranscriptPPT
-
Jul 2015TranscriptPPT
Biologics (41%)[1]
Has one of the largest biosimilar pipelines comprising 28 molecules to be launched over the next decade. [2]
It is among the world’s Top 15 bio-manufacturing companies. Only Indian company to get FDA approval for 3 biosimilar molecules (Trastuzumab, Pegfilgrastim, and Insulin Glargine) [3]
The historic approval of the world’s first interchangeable biosimila-bGlargine, in the U.S. was the key highlight of FY22. [4]